Results 11 to 20 of about 29,860 (191)

Investigation of bedaquiline heteroresistance among Mycobacterium tuberculosis isolates from Pakistan

Microbiology Spectrum
Bedaquiline is a key drug recommended by the WHO for the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB, and its use could potentially shorten treatment duration with improved outcomes.
Faiqa Rashid, Shaukat Iqbal, Sabira Tahseen, Yanlin Zhao   +3 more
doaj   +2 more sources

Tolerability and Efficacy of Chemotherapy Containing Bedaquiline in Patients with Multiple Drug Resistant Pulmonary Tuberculosis

Туберкулез и болезни лёгких, 2022
The objective: to evaluate safety and efficacy of bedaquiline in the treatment of patients with multiple drug resistant tuberculosis (MDR-TB).Subjects and Methods.
O. V. Filinyuk, D. Yu. Schegertsov, N. N. Kabanets, D. E. Amichba   +3 more
doaj   +2 more sources

Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. [PDF]

PLoS ONE, 2019
Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a novel mechanism of action in over 40 years, has already been detected in Mycobacterium tuberculosis. As a new drug, however, there is currently insufficient clinical
Malancha Karmakar, Carlos H M Rodrigues, Kathryn E Holt, Sarah J Dunstan, Justin Denholm, David B Ascher   +5 more
doaj   +3 more sources

Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.

PLoS Medicine, 2016
BackgroundNew drugs for the treatment of tuberculosis (TB) are becoming available for the first time in over 40 y. Optimal strategies for introducing these drugs have not yet been established.
Amber Kunkel, Frank G Cobelens, Ted Cohen   +2 more
doaj   +2 more sources

Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia

Emerging Infectious Diseases
Bedaquiline is currently a key drug for treating multidrug-resistant or rifampin-resistant tuberculosis. We report and discuss the unusual development of resistance to bedaquiline in a teenager in Namibia, despite an optimal background regimen and ...
Gunar Günther, Lusia Mhuulu, Azaria Diergaardt, Viola Dreyer, Maria Moses, Kaarna Anyolo, Nunurai Ruswa, Mareli Claassens, Stefan Niemann, Emmanuel Nepolo   +9 more
doaj   +2 more sources

Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China

Infection and Drug Resistance, 2023
Enyu Tong,1,* Ying Zhou,1,* Zhengwei Liu,2 Yelei Zhu,2 Mingwu Zhang,2 Kunyang Wu,2 Junhang Pan,2 Jianmin Jiang1– 3 1School of Public Health, Hangzhou Normal University, Hangzhou, 311100, People’s Republic of China; 2Tuberculosis Control ...
Tong E, Zhou Y, Liu Z, Zhu Y, Zhang M, Wu K, Pan J, Jiang J   +7 more
doaj   +1 more source

Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia

International Journal of Mycobacteriology
Background: Bedaquiline is one of the core drugs used to treat multidrug-resistant TB (MDR-TB). Delamanid is one of the companion drugs in group C which is used to complete the treatment regimen when drugs in groups A and B can not be used.
Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Susi Subay, Suko Hari Adiono   +5 more
doaj   +2 more sources

Maleate salts of bedaquiline [PDF]

Acta Crystallographica Section E Crystallographic Communications, 2021
Bedaquiline is one of two important new drugs for the treatment of drug-resistant tuberculosis (TB). It is marketed in the US as its fumarate salt, but only a few salts of bedaquiline have been structurally described so far. We present here five crystal structures of bedaquilinium maleate {systematic name: [4-(6-bromo-2-methoxyquinolin-3-yl)-3-hydroxy ...
Matthias Zeller, Susan Bogdanowich-Knipp, Pamela Smith, Dale K. Purcell, Mercy Okezue, Daniel T. Smith, Stephen R. Byrn, Kari L. Clase   +7 more
openaire   +3 more sources

Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China

International Journal of Infectious Diseases, 2020
Objective: The aim of this study was to investigate the molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis (MTB) isolates from Shaanxi, China.
Jian Yang, Yu Pang, Tianhua Zhang, Xiaoping Xian, Yan Li, Rui Wang, Panting Wang, Meng Zhang, Junyang Wang   +8 more
doaj   +1 more source

Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase

Frontiers in Immunology, 2021
Although bedaquiline has advanced the treatment of multidrug-resistant tuberculosis (TB), concerns remain about the cardiotoxic potential of this agent, albeit by unexplored mechanisms.
Gregory R. Tintinger, Annette J. Theron, Helen C. Steel, Moloko C. Cholo, Jan G. Nel, Jan G. Nel, Charles Feldman, Ronald Anderson   +7 more
doaj   +1 more source